Tango Therapeutics, Inc. 4

Crystal Adam, President, R&D of Tango Therapeutics, Inc. (TNGX), exercised 27,000 stock options at $5.20 and sold 27,000 common shares around $29–30 on July 1, 2026 under a Rule 10b5-1 plan.

On July 1, 2026, Crystal Adam, President, R&D of Tango Therapeutics, Inc., exercised 27,000 stock options at an exercise price of $5.20 per share and acquired 27,000 shares of common stock, then immediately sold an aggregate of 27,000 shares of common stock in two open market transactions: 19,629 shares at a weighted average price of $29.3424 per share and 7,371 shares at a weighted average price of $30.2464 per share. The option exercise involved no incremental cash outlay disclosed beyond the exercise price, and the sales, executed under a Rule 10b5-1 trading plan adopted on October 27, 2025, yielded roughly $814,000 in gross proceeds while leaving Ms. Adam with 115,743 shares of common stock held directly after the transactions.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

4

Source Type

sec

Accession

0001193125-26-295124

Alert Tier

6